ena-STUDY-INSTITUT GUSTAVE ROUSSY-04-12-2018-17:17:42:034-106
RNA-seq profiling of NSCLC cell lines exposed to the PARP inhibitor talazoparib.
An isogenic model of ERCC1-deficiency derived from the A549 NSCLC cell line was used for this study; this model consists of an ERCC1-wildtype parental cell line and an ERCC1-knockout cell line  that was generated by zinc-finger targeting of ERCC1 gene. Both cell lines were exposed to the PARPi talazoparib or DMSO (vehicle) for 48h in culture. For each condition, RNA was extracted from cells and subsequently sequenced on a HiSeq 2500 platform (Illumina).
An isogenic model of ERCC1-deficiency derived from the A549 NSCLC cell line was used for this study; this model consists of an ERCC1-wildtype parental cell line and an ERCC1-knockout cell line  that was generated by zinc-finger targeting of ERCC1 gene. Both cell lines were exposed to the PARPi talazoparib or DMSO (vehicle) for 48h in culture. For each condition, RNA was extracted from cells and subsequently sequenced on a HiSeq 2500 platform (Illumina).